Parkinson’s disease (PD) moves slowly, taking decades to develop, and impacting patients over decades of their lives. Considering that this debilitating condition affects over 10
As CRISPR injection mixes have become more readily available to make genome editing easier, it can be difficult to determine what the value is of
In this epilepsy news customer story on STXBP1 epilepsy, we have the pleasure of hearing from Lior Dor and Sagi Gidali from the Rare Smile
Summary: Computational modeling of STXBP1 protein docking with a compound repurposing library revealed a list of 15 drug candidates. Candidates were testing using a validated
Summary Cas12a’s sequence recognition motifs allow access to AT-rich genomes and loci that are less amenable to Cas9 gene editing, showcasing efficient genome editing capabilities.
Thigmotaxis Overview Thigmotaxis is a “wall hugging” behavior exhibited in both zebrafish and mice. Thigmotaxis has been used to model anxiety and stress response. Zebrafish
The Rise of Zebrafish Research In the realm of neuroscience, behavioral studies using animal models are essential for understanding brain functions and developing treatments for
RapidGen™ – Your fast lane to 2024 target validation breakthrough Knock-Out your drug development efforts in 2024 Our RapidGen™ technology executes proof-of-concept or viability testing
Summary Of the over 60 million people worldwide who suffer from epilepsy, approximately one third of them do not respond to available therapies. While genetic
One can kill nematodes by feeding them any number of noxious chemicals, but how effectively can worms predict potential human toxicity of drug leads? Also, given that the dosage is often the difference between a remedy or a poison, how well does the dosage of a drug translate between worms and humans? If worms lack most of the organ systems that would be key targets of drug toxicity, then how do we test toxicity in organ systems that the worms don’t have? We will discuss how InVivo Biosystems addresses these questions when using C. elegans as a model for drug testing.
The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.
An expert in CRISPR genome editing, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models to enable aging, developmental, and disease studies. Our unique in vivo platforms and technologies bridge the gap between cells and mice.
